Literature DB >> 26710662

Smoldering multiple myeloma risk factors for progression: a Danish population-based cohort study.

Rasmus Sørrig1,2, Tobias W Klausen3, Morten Salomo1, Annette J Vangsted1, Brian Østergaard4, Henrik Gregersen5, Ulf Christian Frølund6, Niels F Andersen7, Carsten Helleberg8, Kristian T Andersen9, Robert S Pedersen10, Per Pedersen11, Niels Abildgaard4, Peter Gimsing1.   

Abstract

Several risk scores for disease progression in patients with smoldering multiple myeloma (SMM) have been proposed; however, all have been developed using single-center registries. To examine risk factors for time to progression (TTP) to multiple myeloma (MM) for SMM, we analyzed a nationwide population-based cohort of 321 patients with newly diagnosed SMM registered within the Danish Multiple Myeloma Registry between 2005 and 2014. Significant univariable risk factors for TTP were selected for multivariable Cox regression analyses. We found that both an M-protein ≥30 g/L and immunoparesis significantly influenced TTP (HR 2.7, 95%CI (1.5;4.7), P = 0.001, and HR 3.3, 95%CI (1.4;7.8), P = 0.002, respectively). High free light chain (FLC) ratio did not significantly influence TTP in our cohort. Therefore, our data do not support recent IMWG proposal of identifying patients with FLC ratio above 100 as having ultra high-risk of transformation to MM. Using only immunoparesis and M-protein ≥30 g/L, we created a scoring system to identify low-, intermediate-, and high-risk SMM. This first population-based study of patients with SMM confirms that an M-protein ≥30 g/L and immunoparesis remain important risk factors for progression to MM.
© 2015 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  Immunoparesis; Risk Factors; Smoldering Multiple Myeloma

Mesh:

Substances:

Year:  2016        PMID: 26710662     DOI: 10.1111/ejh.12728

Source DB:  PubMed          Journal:  Eur J Haematol        ISSN: 0902-4441            Impact factor:   2.997


  19 in total

1.  Timing of treatment of smoldering myeloma: early treatment.

Authors:  María-Victoria Mateos; Verónica González-Calle
Journal:  Blood Adv       Date:  2018-11-13

Review 2.  High-risk smoldering myeloma versus early detection of multiple myeloma: Current models, goals of therapy, and clinical implications.

Authors:  Chutima Kunacheewa; Elisabet E Manasanch
Journal:  Best Pract Res Clin Haematol       Date:  2020-01-25       Impact factor: 3.020

3.  Risk stratification of smoldering multiple myeloma: predictive value of free light chains and group-based trajectory modeling.

Authors:  Vernon Wu; Erin Moshier; Siyang Leng; Bart Barlogie; Hearn Jay Cho; Sundar Jagannath; Deepu Madduri; Madhu Mazumdar; Samir Parekh; Ajai Chari
Journal:  Blood Adv       Date:  2018-06-26

4.  Bence Jones proteinuria in smoldering multiple myeloma as a predictor marker of progression to symptomatic multiple myeloma.

Authors:  V González-Calle; J Dávila; F Escalante; A G de Coca; C Aguilera; R López; A Bárez; J M Alonso; R Hernández; J M Hernández; P de la Fuente; N Puig; E M Ocio; N C Gutiérrez; R García-Sanz; M V Mateos
Journal:  Leukemia       Date:  2016-05-02       Impact factor: 11.528

5.  Combined immune score of lymphocyte to monocyte ratio and immunoglobulin levels predicts treatment-free survival of multiple myeloma patients after autologous stem cell transplant.

Authors:  Karen Sweiss; Jonathan Lee; Nadim Mahmud; Gregory S Calip; Youngmin Park; Dolores Mahmud; Damiano Rondelli; Pritesh R Patel
Journal:  Bone Marrow Transplant       Date:  2019-09-16       Impact factor: 5.483

6.  Characterisation of immunoparesis in newly diagnosed myeloma and its impact on progression-free and overall survival in both old and recent myeloma trials.

Authors:  Jennifer L J Heaney; John P Campbell; Gulnaz Iqbal; David Cairns; Alex Richter; J Anthony Child; Walter Gregory; Graham Jackson; Martin Kaiser; Roger Owen; Faith Davies; Gareth Morgan; Janet Dunn; Mark T Drayson
Journal:  Leukemia       Date:  2018-06-20       Impact factor: 11.528

7.  A tertiary center experience of multiple myeloma patients with COVID-19: lessons learned and the path forward.

Authors:  Bo Wang; Oliver Van Oekelen; Tarek H Mouhieddine; Diane Marie Del Valle; Joshua Richter; Hearn Jay Cho; Shambavi Richard; Ajai Chari; Sacha Gnjatic; Miriam Merad; Sundar Jagannath; Samir Parekh; Deepu Madduri
Journal:  J Hematol Oncol       Date:  2020-07-14       Impact factor: 17.388

8.  Intravenous Immunoglobulin G Suppresses Heat Shock Protein (HSP)-70 Expression and Enhances the Activity of HSP90 and Proteasome Inhibitors.

Authors:  Richard J Jones; Ram K Singh; Fazal Shirazi; Jie Wan; Hua Wang; Xiaobin Wang; Min Jin Ha; Muhamed Baljevic; Isere Kuiatse; Richard E Davis; Robert Z Orlowski
Journal:  Front Immunol       Date:  2020-08-13       Impact factor: 7.561

9.  Testing Mayo Clinic's New 20/20/20 Risk Model in Another Cohort of Smoldering Myeloma Patients: A Retrospective Study.

Authors:  Camille Tessier; Thomas Allard; Jean-Samuel Boudreault; Rayan Kaedbey; Vincent Éthier; Fléchère Fortin; Michel Pavic
Journal:  Curr Oncol       Date:  2021-05-26       Impact factor: 3.677

10.  Immunoparesis in newly diagnosed Multiple Myeloma patients: Effects on overall survival and progression free survival in the Danish population.

Authors:  Rasmus Sørrig; Tobias W Klausen; Morten Salomo; Annette J Vangsted; Ulf Christian Frølund; Kristian T Andersen; Anja Klostergaard; Carsten Helleberg; Robert S Pedersen; Per T Pedersen; Sissel Helm-Petersen; Elena Manuela Teodorescu; Birgitte Preiss; Niels Abildgaard; Peter Gimsing
Journal:  PLoS One       Date:  2017-12-07       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.